04/17/2024 – 15:59
Biomm announced this Wednesday, 17th, that it signed an agreement to market and distribute the drug semaglutide in Brazil, for the treatment of diabetes, but which has been widely used by people interested in reducing weight.
The announcement involving the similar drug to Ozempic, from the European Novo Nordisk, caused Biomm's shares to jump more than 30%, although with low volume this afternoon.
+Gold pauses rally and closes lower, interrupting a sequence of 6 high sessions
The exclusive agreement was reached with the Indian Biocon. Biomm stated that, last year, sales of semaglutide in Brazil totaled 3.1 billion reais, with an average growth rate of almost 40% between 2021 and 2023.
At 3:11 pm, Biomm's shares showed an increase of 36.8%, quoted at 15.20 reais, after rising close to 40% earlier. Business volume, however, was low, with 740 operations on time.
Under the agreement, Biocon will be responsible for the development, manufacture and supply of semaglutide to Biomm for the Brazilian market.
But the company stated that commercialization and distribution in Brazil depend on registration with the National Health Surveillance Agency (Anvisa). Biomm also stated that the sale of the medicine also depends on the publication of the price by the Medicines Market Regulation Chamber (CMED), as well as the expiration of the patent, which should occur in mid-2026.
When contacted, Anvisa was unable to comment on the matter immediately.
Biomm is expected to inaugurate an insulin glargine factory, the first from a Brazilian company, in Nova Lima (MG), on the 26th. The event should be attended by President Luiz Inácio Lula da Silva and the Minister of Health, Nísia Trindade Lima, said the company.
#Biomm #soars #stock #market #agreement #similar #Ozempic #Brazil